← Eichor
Study identifier: NCT07108998 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Study of Epcoritamab as a Consolidation Therapy in CLL/SLL

Condition: CLL/SLL · CLL · SLL  ·  Sponsor: Zulfa Omer

PhasePhase 2
Planned participants22
Who can joinAll sexes, 18 Years to no upper limit
Healthy volunteersNo

About this study

This is a phase 2 study of Epcoritamab as a consolidation therapy for 2nd generation BTKi +/- Obinutuzumab in CLL/SLL patients or patients with variants of this.

This description comes directly from the study's public registry record.

Talk to the study team

UCCC Clinical Trials Office  ·  513-584-7698  ·  cancer@uchealth.com

Zulfa Omer, MD

Always discuss trial participation with your own doctor first.

Locations (1)

University of CincinnatiCincinnati, Ohio, United StatesRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT07108998